Skip to content

Study · Systematic review · 2019

9 results

Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.

Mishriky BM, Cummings DM, Powell JR, Sewell KA, Tanenberg RJ

Diabetes & metabolism20 Sept 2018Cited by 17 (Europe PMC)

PMID30243806 (opens in a new tab)DOI10.1016/j.diabet.2018.09.002 (opens in a new tab)PepBankPUB-30243806
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, once-weekly semaglutide lowered HbA1c more than other GLP-1 receptor agonists in a meta-analysis.

    In plain wordsIn adults with type 2 diabetes, weekly semaglutide lowered HbA1c more than other GLP-1 drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change versus other GLP-1RA
    Study

    n: not reported in source

    Comparator
    Other GLP-1RA
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in HbA1c
    −0.38%
    vs other GLP-1RA

    Source sentences

    Summary
    There was a significantly greater reduction in haemoglobin A1c favouring semaglutide when compared to other GLP-1RA or DPP-4i [MD (95% CI) = -0.38% (-0.62, -0.15)
    1 context sentence
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, once-weekly semaglutide lowered HbA1c more than DPP-4 inhibitors in a meta-analysis.

    In plain wordsIn adults with type 2 diabetes, weekly semaglutide lowered HbA1c more than DPP-4 inhibitor tablets.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change versus DPP-4 inhibitors
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in HbA1c
    −1.14%
    vs DPP-4i

    Source sentences

    Summary
    There was a significantly greater reduction in haemoglobin A1c favouring semaglutide when compared to other GLP-1RA or DPP-4i [MD (95% CI) = -0.38% (-0.62, -0.15) and -1.14% (-1.53, -0.75) respectively].
    1 context sentence
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, once-weekly semaglutide produced greater weight loss than other GLP-1 receptor agonists in a meta-analysis.

    In plain wordsIn adults with type 2 diabetes, weekly semaglutide led to more weight loss than other GLP-1 drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss versus other GLP-1RA
    Study

    n: not reported in source

    Comparator
    Other GLP-1RA
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in weight
    −2.5 kg
    vs other GLP-1RA

    Source sentences

    Summary
    There was a significantly greater weight loss favouring semaglutide when compared to other GLP-1RA or DPP-4i [MD (95% CI) = -2.50 kg (-3.91, -1.09)
    1 context sentence
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, once-weekly semaglutide produced greater weight loss than DPP-4 inhibitors in a meta-analysis.

    In plain wordsIn adults with type 2 diabetes, weekly semaglutide led to more weight loss than DPP-4 inhibitor tablets.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss versus DPP-4 inhibitors
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in weight
    −3.19 kg
    vs DPP-4i

    Source sentences

    Summary
    There was a significantly greater weight loss favouring semaglutide when compared to other GLP-1RA or DPP-4i [MD (95% CI) = -2.50 kg (-3.91, -1.09) and -3.19 kg (-3.66, -2.72) respectively].
    1 context sentence
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a greater proportion reached glycaemic goals with semaglutide than with other GLP-1 receptor agonists.

    In plain wordsIn adults with type 2 diabetes, more people reached blood sugar goals on weekly semaglutide than on other GLP-1 drugs.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion reaching glycaemic goals versus other GLP-1RA
    Study

    n: not reported in source

    Comparator
    Other GLP-1RA
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The proportion of patients achieving glycaemic goals and goal weight loss was greater in semaglutide-treated patients when compared to either other GLP-1RA or DPP-4i.
    1 context sentence
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a greater proportion reached glycaemic goals with semaglutide than with DPP-4 inhibitors.

    In plain wordsIn adults with type 2 diabetes, more people reached blood sugar goals on weekly semaglutide than on DPP-4 inhibitor tablets.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion reaching glycaemic goals versus DPP-4 inhibitors
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The proportion of patients achieving glycaemic goals and goal weight loss was greater in semaglutide-treated patients when compared to either other GLP-1RA or DPP-4i.
    1 context sentence
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a greater proportion reached goal weight loss with semaglutide than with other GLP-1 receptor agonists.

    In plain wordsIn adults with type 2 diabetes, more people reached the weight loss goal on weekly semaglutide than on other GLP-1 drugs.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion reaching goal weight loss versus other GLP-1RA
    Study

    n: not reported in source

    Comparator
    Other GLP-1RA
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The proportion of patients achieving glycaemic goals and goal weight loss was greater in semaglutide-treated patients when compared to either other GLP-1RA or DPP-4i.
    1 context sentence
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a greater proportion reached goal weight loss with semaglutide than with DPP-4 inhibitors.

    In plain wordsIn adults with type 2 diabetes, more people reached the weight loss goal on weekly semaglutide than on DPP-4 inhibitor tablets.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion reaching goal weight loss versus DPP-4 inhibitors
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The proportion of patients achieving glycaemic goals and goal weight loss was greater in semaglutide-treated patients when compared to either other GLP-1RA or DPP-4i.
    1 context sentence
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.
  9. 09HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, semaglutide-treated patients had a significantly higher incidence of gastrointestinal side effects than with other incretin-based therapies.

    In plain wordsIn adults with type 2 diabetes, weekly semaglutide caused more stomach and gut side effects than other GLP-1 or DPP-4 drugs.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal side effects
    Study

    n: not reported in source

    Comparator
    Other incretin-based therapies
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, semaglutide-treated patients had a significantly higher incidence of gastrointestinal side effects.
    2 context sentences
    Summary · context
    However, this potent effect of semaglutide was associated with a higher incidence of gastrointestinal side effects.
    Summary · context
    We searched for randomized trials comparing once-weekly semaglutide to other incretin-based therapies in patients with type 2 diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.